BRAFTOVI regimen showed a 51% reduced risk of death vs. standard chemo (HR 0.49). Median survival with BRAFTOVI combo reached 30.3 months vs. 15.1 months for chemo. Rebound or breakdown? See how ...

Pfizer Inc. (NYSE:PFE) on Friday released data from Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with cetuximab (marketed as ERBITUX) and mFOLFOX6 (fluorouracil ...

Amp up your arm gains with a triset that hits every angle.

Cooper G and Tomanek R (1982) Load regulation of the structure, composition, and function of mammalian myocardium., Circulation Research, 50:6, (788-798), Online publication date: 1-Jun-1982. Chilian ...

An assessment of their significance in the absence of valvar stenosis., Heart, 10.1136/hrt.53.6.640, 53:6, (640-644), Online publication date: 1-Jun-1985. NISHIMURA R , MILLER F , CALLAHAN M , BENASSI ...